TORONTO, March 13 /CNW/ - Spectral today announces key presentations at a
symposium focusing on Endotoxemia at the 7th World Congress on Trauma, Shock,
Inflammation and Sepsis, in Munich Germany. The session will feature results
of clinical studies using the Endotoxin Activity Assay (EAA(TM)) presented by
internationally renowned physicians.
These studies demonstrate the usefulness of the EAA(TM) in several
different clinical conditions. A number of key reports will be made at this
- Henry Ford Hospital in Detroit, a world leader in the use of early,
goal oriented treatment of sepsis, will present the results of a
study on the use of EAA(TM) to identify patients who require early
aggressive management of impending sepsis.
- Rockefeller University in New York, whose study has identified that
elevated endotoxin levels are a risk factor for adverse events for
patients on chronic haemodialysis, will present results on the use of
EAA(TM) in patients with end stage renal disease.
- University of Texas, South Western, Parkland Hospital, where EAA(TM)
has been studied in patients with varying levels of burn injury and
in conjunction with a potential anti-endotoxin therapy for these
patients, will present its results.
In addition, results will be presented from a systematic review of the
literature showing favourable outcomes for patients treated with an
anti-endotoxin therapy, Toray Medical's "Toraymyxin", an endotoxin removal
system for patients with sepsis. Spectral and Toray Medical continue to work
closely together to provide a sepsis management strategy, which includes a
tool for patient selection (Spectral's EAA(TM)) and treatment (Toray's
"We are pleased to see these reports on the utility of the EAA(TM) in the
management of critically ill patients," stated Dr. Paul Walker, President &
CEO of Spectral. "These activities support the extensive distribution network
we are building across Europe. The use of the EAA(TM) consistently
demonstrates the utility of endotoxin measurements in a variety of critical
conditions, both as a marker for risk of bad outcomes and as a guide to
appropriate therapy," added Dr. Walker.
Spectral is a developer of innovative technologies for comprehensive
disease management. Spectral provides accurate and timely information to
clinicians enabling the early initiation of appropriate and targeted therapy.
Current products include Spectral's FDA approved rapid diagnostic for West
Nile Virus (RapidWN(TM)) and its FDA approved rapid diagnostic for sepsis
(EAA(TM)) as well as a range of other biological reagents. Spectral's common
shares are listed on The Toronto Stock Exchange under the symbol SDI.
Information in this news release that is not current or historical
factual information may constitute forward-looking information within the
meaning of securities laws. Implicit in this information, particularly in
respect of the future outlook of Spectral and anticipated events or results,
are assumptions based on beliefs of Spectral's senior management as well as
information currently available to it. While these assumptions were considered
reasonable by Spectral at the time of preparation, they may prove to be
incorrect. Readers are cautioned that actual results are subject to a number
of risks and uncertainties, including the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Spectral to take advantage of business opportunities
in the biomedical industry, the granting of necessary approvals by regulatory
authorities as well as general economic, market and business conditions, and
could differ materially from what is currently expected.
For further information:
For further information: Spectral Diagnostics Inc., Dr. Paul Walker,
Chief Executive Officer, (416) 626-3233